Defiance Research
Research, with its record intact.
Public research preprints, their stated evidence boundaries, and the cryptographic receipt that identifies each issued revision.
Published research preprints
Research preprint · Revision 1
L-Carnitine L-Tartrate and Skeletal Muscle Androgen Receptor Protein: A Critical Evidence Map with an Unresolved Testosterone Therapy Hypothesis
A formulation-aware appraisal of exposure, muscle carnitine, receptor function, and an untested testosterone interaction
L-Carnitine L-tartrate is frequently linked to muscle metabolism and androgen signaling, but material identity, plasma exposure, tissue uptake, pathway flux, receptor abundance, receptor function, and clinical response are different evidence layers. This critical narrative review and curated evidence map separates LCLT from free and prescription levocarnitine and from other carnitine formulations. It incorporates direct null and heterogeneous LCLT trials, current regulatory records, microbial TMAO evidence, corrections, and retractions through 30 July 2026. The pivotal androgen receptor evidence is one corrected crossover study in ten young resistance-trained men. It reported a preexercise total skeletal muscle androgen receptor protein difference but did not measure muscle carnitine, receptor localization or occupancy, transcription, protein synthesis, hypertrophy, or response to prescribed testosterone. Paired uncertainty cannot be reconstructed from the published aggregate data, and no independent replication or controlled LCLT-by-testosterone experiment was identified. Revision 1 therefore presents explicit causal boundaries, eleven quantitative definitions, competing interaction hypotheses, and a staged falsification program. It does not establish synergy, therapeutic benefit, a clinical regimen, or suitability for human use.
Research preprint · Revision 4
Vesugen (Lys-Glu-Asp) and Retinal Disease
A Claim-Deconvolution and Evidence Map of the 1,500-Patient Peptide-Bioregulator Report
Vesugen is marketed and discussed as a vascular peptide bioregulator relevant to retinal disease. The strongest clinical narrative describes 1,500 patients treated from 1995 through 2010 for macular degeneration, diabetic retinopathy, retinitis pigmentosa, and other eye diseases. It reports improved visual functions in 95%, no change in 5%, and no worsening, based on visual acuity, electrophysiology, eye imaging, and subjective status [1]. This is a large, consistently favorable observational signal for the individualized multipeptide treatment program and must not be characterized as no evidence. The report does not provide a control group, protocol-defined response threshold, disease-stratified effects, participant flow, or component-level treatment allocation. It therefore supports that the program may be clinically active while leaving the size of Vesugen's separate contribution unquantified. Patent mapping corrects a consequential identity error. RU 2177801, cited beside the article's antiangiogenesis statement, names L-Lys-L-Glu, a dipeptide, not Vesugen/KED [2]. The Vesugen-associated patent RU 2295970 names H-Lys-Glu-Asp-OH and claims increased capillary resistance and treatment of microcirculatory disorders by parenteral administration [3]. Its human examples concern skin capillary fragility in hypovitaminosis and senile purpura, not retinal disease. One example also states 25 total participants while separately reporting 18 controls, implying only seven treated participants if both figures are correct. RU 2301072 concerns Ventfort, an animal-vessel extract containing a range of peptide components, not pure KED [4]. RU 2157154 describes combined Retilin, Cortexin, and Epithalamin treatment for diabetic retinopathy and does not include Vesugen [5]. Patent RU 2363488 concerns another molecule reported to stimulate angiogenesis, demonstrating why directionally different mechanisms cannot be pooled under a peptide-class label [6]. Vesugen/Vezugen also has positive non-retinal human results. Reports describe favorable clinical or microcirculatory outcomes in lower-limb ischemia and vasculogenic erectile dysfunction, improvement in a mixed chemical-stomatitis regimen, favorable occupational and biological-age outcomes in combinations with Pinealon, and favorable atherosclerosis comparisons [11,25-30]. These findings support human biological activity and a potentially beneficial vascular role, although they are small, incompletely controlled, sometimes combination-based, and contain reporting discrepancies. They are supportive evidence, not zero evidence, and they remain relevant even though they do not directly measure the human retina. The wider retinal peptide program contains additional positive evidence. A 2001 comparative report included 104 patients given Retinalamin, Epithalamin, and Cortexin and 42 controls; it reported visual-acuity improvement in 90%, improved fundus findings, functional activity, and retinal blood flow, with no negative clinical changes [12]. A 2024 56-person Retinalamin comparison reported favorable structural and electrophysiological findings [13]. Epithalon and Retinalamin studies also report positive retinal-model results [14-16]. These findings strengthen the plausibility of peptide-based retinal treatment, but the tested materials differ from KED and therefore provide supportive class-program context rather than Vesugen-only proof. The full pharmacologic chain for KED remains largely unmeasured. The reference structure is C15H26N4O8 with average molecular mass 390.393 Da [17]. The patent reports H-Lys-Glu-Asp-OH acetate with 98.15% HPLC purity, 6% moisture, pH 4.77, and optical rotation of -31 degrees [3]. Current commercial capsule and sublingual pages instead describe amino-acid ingredients or AC-2 and do not establish covalently linked, sequence-verified intact KED [31,32]. No verified human route-specific absorption, intact plasma exposure, half-life, metabolites, tissue distribution, blood-retinal barrier passage, retinal concentration, receptor or molecular target occupancy, dose-response, pharmacodynamic bridge, or ocular elimination dataset was identified. General transport theory cannot replace KED-specific measurement. The balanced conclusion is that the evidence contains multiple positive signals and no qualifying evidence that Vesugen is ineffective for retinal disease. The 1,500-patient series supports a favorable signal for the complete multipeptide program; non-retinal Vesugen studies and KED experiments support biological and vascular activity; and other retinal peptides supply positive program-level context. Vesugen's independent retinal effect, optimal route, magnitude of benefit, and exposure-response relationship have not yet been isolated. Vesugen should therefore be classified as a promising retinal adjunct with positive but non-isolated evidence, not as an ineffective product and not as a proven monotherapy.
Research preprint · Revision 4
Nicotinamide Riboside, Nicotinamide Mononucleotide, and NAD+
A Comparative Evidence Map of NAD Target Engagement and Route Pharmacology
NR, NMN, and NAD+ are often presented as competing ways to replenish nicotinamide adenine dinucleotide. That framing compresses several different pharmacologic questions into one. NR is a nucleoside, NMN is a phosphorylated nucleotide, and NAD+ is a larger dinucleotide. Their administered forms encounter different stability, transport, extracellular metabolism, gut microbial transformation, first-pass handling, cellular entry, subcellular transport, and clearance constraints. A comparison that ignores route and compartment can reward an invasive route for bypassing the gut or reward a blood biomarker that does not establish tissue delivery. This paper constructs a route-resolved evidence map through 7 August 2026. Priority was given to primary human trials, human PK/PD studies, primary isotope-tracing and transporter studies required to interpret molecular fate, trial registries, and official regulatory records. A 2026 PRISMA-guided systematic review was used as a coverage cross-check, not as a substitute for primary evidence [50]. Evidence was adjudicated at claim level using explicit labels: established background, direct human observation, derived calculation, mechanistic inference, unresolved conflict, unknown, and contradicted claim. The best direct comparative evidence concerns oral NR and NMN. In a randomized, open-label, placebo-controlled trial in 65 analyzed healthy adults, 1,000 mg/day NR (3.4 mmol/day) and 1,000 mg/day NMN (3.0 mmol/day) for 14 days increased baseline whole-blood NAD+ by placebo-adjusted 49.4 umol/L and 43.1 umol/L, respectively. The authors concluded the effects were comparable. A simple derived normalization gives 14.5 and 14.4 umol/L per administered mmol/day, a difference of about 1 percent. In a separate randomized open-label crossover PK study in six healthy adults, 1,200 mg/day of each precursor for eight days raised blood NAD more with NR than NMN; the reported difference remained significant after molecular-weight adjustment. Brain NAD did not differ between precursors during that short stage. The larger trial supports practical equivalence at its tested regimen; the smaller within-person trial supports a provisional NR advantage in blood response under its regimen. Differences in design, regimen, baseline, product, sampling, and analysis prevent a definitive synthesis. Human oral NR has the most mature evidence base for dose-responsive whole-blood NAD elevation, repeated dosing, high-dose short-term safety, and cerebral target engagement. Human oral NMN also raises blood NAD and has several short randomized trials, including a rigorous study that improved clamp-measured muscle insulin sensitivity in a specific population. Direct oral NAD+ remains preliminary and formulation-dependent. IV NAD+ is rapidly removed from plasma at the only directly studied human infusion rate, produces metabolites compatible with extracellular enzymatic cleavage, and is partly recovered through urinary NAD+ and methyl-nicotinamide. It can be difficult to tolerate at faster commercial infusion rates and has not been shown to provide general intact-cell delivery or clinical superiority. SC NAD+ has no published human PK or efficacy basis from which target engagement can be calculated. The defensible ranking is conditional. For oral whole-blood NAD target engagement at approximately gram-scale tested regimens, NR and NMN are effectively tied, with a provisional NR edge that requires replication. For evidence maturity and human cerebral target engagement, NR ranks first. For direct evidence of a metabolic clinical effect in postmenopausal women with prediabetes, NMN has a positive trial, but that does not generalize to other populations or outcomes. Direct oral NAD+ ranks behind both precursors because its evidence is too formulation-specific and unreplicated. IV NAD+ is not ranked against oral agents because the route, burden, safety, and estimand differ. SC NAD+ is unrankable because the necessary human data are absent. No compound is proven superior for longevity or broad clinical benefit.
Research preprint · Revision 1
Four-Agent Adipose and Energy Modulation: Evidence, Translational Limits, and Interaction Risk
A bounded mechanistic analysis of yohimbine, clenbuterol, retatrutide, and 5-Amino-1MQ
Four agents are frequently joined in informal body-composition narratives because they affect different parts of energy intake, adrenergic signaling, adipose lipid mobilization, or nicotinamide metabolism. That apparent pathway coverage does not establish compatibility, persistence on a common time scale, or improved fat loss. This paper adversarially evaluates yohimbine, clenbuterol, retatrutide, and 5-Amino-1MQ at the levels of material identity, target pharmacology, acute biomarkers, sustained human outcomes, preclinical findings, regulatory state, and interaction risk. The evidence is sharply asymmetric. Retatrutide has randomized human outcome evidence while remaining investigational, yohimbine and clenbuterol have limited and context-dependent human evidence with material safety constraints, and 5-Amino-1MQ remains preclinical. No controlled pairwise or four-agent efficacy, pharmacokinetic-interaction, or safety trial was identified. The paper therefore presents a bounded interaction hypothesis, quantitative estimands, explicit failure modes, and a staged validation pathway rather than a treatment protocol or demonstrated synergy claim.
Research preprint · Revision 4
Precision Accelerated Repair Biology: A Bounded Mechanistic Evidence Map for a 20-Material Case Set
Detailed non-clinical research edition derived from a restricted source manuscript
Multicomponent repair proposals routinely join materials with unequal chemical definition, target knowledge, exposure data, and evidentiary maturity. This paper audits a closed historical case set of two physiologically regulated ion contexts and eighteen peptide or peptide-derived labels. Revision 4 retains the multilingual primary-source recovery pass and adds one separately bounded 2026 KPV study in oleic-acid-treated HepG2 cells. It maps bounded propositions concerning mitochondrial state, apoptotic commitment, inflammatory signaling, cell migration, endothelial behavior, matrix organization, neural state, and cell-state persistence. The paper does not claim that the twenty labels form a validated therapeutic system, share pharmacology, or improve a general repair outcome. The contribution is a claim-level evidence map, a transparent identity and uncertainty record, and a narrow synthetic design example. The evidence map is curated rather than systematic; it has an explicit cutoff and does not establish clinical safety, efficacy, compatibility, optimal timing, or benefit of any combination.